 "Merck to expand Carlsbad facility in US")
Merck, the Germany-based science and technology company, to expand its Carlsbad (California, USA) facility to meet growing demand for viral and gene therapy products. Scheduled for completion in 2016, the Carlsbad campus will increase from 44,000 square feet to 65,000 square feet, with 16 modular viral bulk manufacturing cleanroom suites, two fill/finish suites and twice the warehouse capacity. The expansion will incorporate single-use equipment in a flexible, scalable format for clinical and commercial bulk drug production.
“We are building on our industry-leading offerings in the manufacturing and testing of innovative and complex products, underscoring our commitment to being a trusted, long-term partner of choice,” said Udit Batra, member of the Merck executive board and CEO, Life Science. The company’s new capacity at Carlsbad positions Merck to seamlessly support customers from clinical to commercial scales, and is complemented by cell-banking services in Rockville, Maryland, viral and gene therapy manufacturing capacity in Glasgow, Scotland and global BioReliance biosafety testing offering.
The Carlsbad facility - Merck’s flagship site for SAFC's viral and gene therapies offering - will remain fully operational throughout the expansion. The Carlsbad campus features segregated fill/finish capacity for gene therapy, viral vaccine and immunotherapy products. Merck’s teams have decades of combined experience in the viral, gene therapy and biosafety testing sectors.
“We are building on our industry-leading offerings in the manufacturing and testing of innovative and complex products, underscoring our commitment to being a trusted, long-term partner of choice,” said Udit Batra, member of the Merck executive board and CEO, Life Science. The company’s new capacity at Carlsbad positions Merck to seamlessly support customers from clinical to commercial scales, and is complemented by cell-banking services in Rockville, Maryland, viral and gene therapy manufacturing capacity in Glasgow, Scotland and global BioReliance biosafety testing offering.
The Carlsbad facility - Merck’s flagship site for SAFC's viral and gene therapies offering - will remain fully operational throughout the expansion. The Carlsbad campus features segregated fill/finish capacity for gene therapy, viral vaccine and immunotherapy products. Merck’s teams have decades of combined experience in the viral, gene therapy and biosafety testing sectors.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%